journal article·2025-06-03Open access

The Bacterial Outer Membrane Vesicle-Cloaked Immunostimulatory Nanoplatform Reinvigorates T Cell Function and Reprograms Tumor Immunity

Yu-Han Lin, Chia-Wei Chen, Mei-Yi Chen, Li Xu, Xuejiao Tian, Siu-Hung Cheung, Yen-Ling Wu, Natnaree Siriwon, Si-Han Wu, Kurt Yun Mou

ACS Nano· Volume 19· Issue 21

Abstract

Bacterial outer membrane vesicles (OMVs) represent powerful immunoadjuvant nanocarriers with the capacity to reprogram the tumor microenvironment (TME) and activate immune responses. Here, we investigate a nanotherapeutic platform integrating immunostimulatory cytosine-phosphate-guanine oligodeoxynucleotides (CpG-ODNs, hereafter termed CpG) into mesoporous silica nanoparticles cloaked with OMVs (CpG@MSN-PEG/PEI@OMVs) for cancer immunotherapy. Systemic administration of these nanohybrids facilitates precise tumor targeting, induces antitumor cytokines such as IFNγ, and suppresses immunosuppressive cytokine TGF-β, reshaping the TME. Additionally, CpG@MSN-PEG/PEI@OMVs promote M1 macrophage polarization, dendritic cell maturation, and the generation of durable tumor-specific immune memory, resulting in pronounced tumor regression with minimal systemic toxicity. The platform demonstrates efficacy against metastatic and solid tumor models including 4T1 breast and MC38 colorectal cancers. Transcriptomic analyses reveal that CpG@MSN-PEG/PEI@OMVs enhance mitochondrial oxidative phosphorylation in T cells within tumor-draining lymph nodes, mitigating T cell exhaustion and restoring metabolic fitness. These results support the potential of CpG@MSN-PEG/PEI@OMVs as a modular nanoplatform to modulate innate and adaptive immunity in cancer immunotherapy.
Source: openalex_inverted_index · Quality: baseline

Research context

OpenAlex topics: Nanoplatforms for cancer theranostics · Immunotherapy and Immune Responses · Cancer Research and Treatments

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

Taiwan International Graduate Program in Molecular Medicine

National Yang Ming Chiao Tung University and Academia Sinica

Graduate Institute of Nanomedicine and Medical Engineering

Taipei Medical University

Institute of Biomedical Sciences

Academia Sinica

Research Center for Applied Sciences

Nano Science and Technology Program, Taiwan International Graduate Program

Department of Engineering and System Science

National Tsing Hua University

Chakri Naruebodindra Medical Institute, Faculty of Medicine Ramathibodi Hospital

Mahidol University

International Ph.D. Program in Biomedical Engineering

Funding

National Health Research Institutes · Academia Sinica · National Science and Technology Council · Ministry of Education, Taiwan

References (91)

Show source-provided references
1. 10.1128/mmbr.00031-0910.1128/mmbr.00031-09 ↗
2. 10.1038/nature2134910.1038/nature21349 ↗
3. 10.1038/s41392-022-01270-x10.1038/s41392-022-01270-x ↗
4. 10.1056/nejmoa100346610.1056/nejmoa1003466 ↗
5. 10.1016/j.cell.2017.01.01710.1016/j.cell.2017.01.017 ↗
6. 10.1146/annurev-med-092012-11280710.1146/annurev-med-092012-112807 ↗
7. 10.1039/D3RA01153D10.1039/D3RA01153D ↗
8. 10.1016/j.it.2010.04.00210.1016/j.it.2010.04.002 ↗
9. 10.1038/s41590-021-00949-710.1038/s41590-021-00949-7 ↗
10. 10.1016/j.semnephrol.2012.04.00910.1016/j.semnephrol.2012.04.009 ↗
11. 10.1038/s41578-021-00358-010.1038/s41578-021-00358-0 ↗
12. 10.1002/smll.20240902110.1002/smll.202409021 ↗
13. 10.1128/iai.00920-1910.1128/iai.00920-19 ↗
14. 10.3389/fimmu.2024.142744310.3389/fimmu.2024.1427443 ↗
15. 10.1002/adma.20230615810.1002/adma.202306158 ↗
16. 10.1038/s41551-024-01191-w10.1038/s41551-024-01191-w ↗
17. 10.1002/adma.20170675910.1002/adma.201706759 ↗
18. 10.1038/s41467-022-33889-310.1038/s41467-022-33889-3 ↗
19. 10.1016/j.jconrel.2022.05.06210.1016/j.jconrel.2022.05.062 ↗
20. 10.1038/s41467-017-00729-810.1038/s41467-017-00729-8 ↗
21. 10.1016/j.apsb.2020.02.00210.1016/j.apsb.2020.02.002 ↗
22. 10.3390/immuno203003010.3390/immuno2030030 ↗
23. 10.1002/adma.20200208510.1002/adma.202002085 ↗
24. 10.1189/jlb.3MR0316-118RR10.1189/jlb.3MR0316-118RR ↗
25. 10.1080/14737140.2021.191513610.1080/14737140.2021.1915136 ↗
26. 10.3390/bios1202007110.3390/bios12020071 ↗
27. 10.20517/evcna.2023.2110.20517/evcna.2023.21 ↗
28. 10.1016/j.carbpol.2015.04.07010.1016/j.carbpol.2015.04.070 ↗
29. 10.1038/s41571-024-00859-110.1038/s41571-024-00859-1 ↗
30. 10.3390/cancers1318461610.3390/cancers13184616 ↗
31. 10.4049/jimmunol.220095010.4049/jimmunol.2200950 ↗
32. 10.3389/fnagi.2020.0003610.3389/fnagi.2020.00036 ↗
33. 10.1016/j.apsb.2015.07.00510.1016/j.apsb.2015.07.005 ↗
34. 10.1038/s41467-020-15188-x10.1038/s41467-020-15188-x ↗
35. 10.1186/1471-2407-13-28910.1186/1471-2407-13-289 ↗
36. 10.3390/ijms2401039510.3390/ijms24010395 ↗
37. 10.1038/s41598-019-51149-110.1038/s41598-019-51149-1 ↗
38. 10.1016/j.tranon.2023.10186610.1016/j.tranon.2023.101866 ↗
39. 10.1080/2162402X.2015.106117510.1080/2162402X.2015.1061175 ↗
40. 10.4049/jimmunol.110229610.4049/jimmunol.1102296 ↗
41. 10.1038/s41467-021-24591-x10.1038/s41467-021-24591-x ↗
42. 10.1016/S0952-7915(00)00218-110.1016/S0952-7915(00)00218-1 ↗
43. 10.1038/s41416-020-0924-510.1038/s41416-020-0924-5 ↗
44. 10.1186/s40364-020-00228-x10.1186/s40364-020-00228-x ↗
45. 10.1186/s12967-018-1611-710.1186/s12967-018-1611-7 ↗
46. 10.1073/pnas.80.17.539710.1073/pnas.80.17.5397 ↗
47. 10.1038/s41419-021-04151-310.1038/s41419-021-04151-3 ↗
48. 10.1007/s13402-016-0280-x10.1007/s13402-016-0280-x ↗
49. 10.1038/s41467-021-22755-310.1038/s41467-021-22755-3 ↗
50. 10.1038/bjc.2015.10110.1038/bjc.2015.101 ↗
51. 10.1136/jitc-2023-00671410.1136/jitc-2023-006714 ↗
52. 10.1158/2159-8290.CD-21-042510.1158/2159-8290.CD-21-0425 ↗
53. 10.1002/path.587710.1002/path.5877 ↗
54. 10.1002/mco2.610.1002/mco2.6 ↗
55. 10.1016/j.molmed.2017.11.00510.1016/j.molmed.2017.11.005 ↗
56. 10.1038/s41590-021-00940-210.1038/s41590-021-00940-2 ↗
57. 10.1038/s41590-020-0793-310.1038/s41590-020-0793-3 ↗
58. 10.1038/s41590-020-0725-210.1038/s41590-020-0725-2 ↗
59. 10.1038/s41421-023-00578-410.1038/s41421-023-00578-4 ↗
60. 10.3389/fonc.2020.0178710.3389/fonc.2020.01787 ↗
61. 10.1038/s41419-018-0889-y10.1038/s41419-018-0889-y ↗
62. 10.3389/fmolb.2021.61150810.3389/fmolb.2021.611508 ↗
63. 10.1038/s41467-022-31250-210.1038/s41467-022-31250-2 ↗
64. 10.1126/science.272.5265.117910.1126/science.272.5265.1179 ↗
65. 10.3390/ijms1810211410.3390/ijms18102114 ↗
66. 10.1038/ncomms1549410.1038/ncomms15494 ↗
67. 10.3390/cancers1321527910.3390/cancers13215279 ↗
68. 10.1093/jleuko/qiae00110.1093/jleuko/qiae001 ↗
69. 10.3389/fimmu.2019.0108410.3389/fimmu.2019.01084 ↗
70. 10.1126/sciimmunol.aaz441510.1126/sciimmunol.aaz4415 ↗
71. 10.1038/srep3585510.1038/srep35855 ↗
72. 10.3389/fcell.2022.81692710.3389/fcell.2022.816927 ↗
73. 10.1158/0008-5472.CAN-16-061810.1158/0008-5472.CAN-16-0618 ↗
74. 10.1038/s41577-021-00598-910.1038/s41577-021-00598-9 ↗
75. 10.1038/s41586-021-03326-410.1038/s41586-021-03326-4 ↗
76. 10.1038/s41423-023-01118-610.1038/s41423-023-01118-6 ↗
77. 10.4161/onci.2384910.4161/onci.23849 ↗
78. 10.3389/fimmu.2022.93407810.3389/fimmu.2022.934078 ↗
79. 10.1038/s41590-022-01210-510.1038/s41590-022-01210-5 ↗
80. 10.3389/fimmu.2018.0120910.3389/fimmu.2018.01209 ↗
81. 10.1016/j.cyto.2015.02.00710.1016/j.cyto.2015.02.007 ↗
82. 10.1182/blood-2005-09-377510.1182/blood-2005-09-3775 ↗
83. 10.3389/fimmu.2023.103019810.3389/fimmu.2023.1030198 ↗
84. 10.1038/s41568-019-0138-410.1038/s41568-019-0138-4 ↗
85. 10.1038/s41590-020-00810-310.1038/s41590-020-00810-3 ↗
86. 10.1186/s13059-019-1921-y10.1186/s13059-019-1921-y ↗
87. 10.1038/s41590-022-01319-710.1038/s41590-022-01319-7 ↗
88. 10.1039/c3cs35405a10.1039/c3cs35405a ↗
89. 10.1172/jci.insight.15103910.1172/jci.insight.151039 ↗
90. 10.1016/j.biomaterials.2016.10.03710.1016/j.biomaterials.2016.10.037 ↗
91. 10.1089/omi.2011.011810.1089/omi.2011.0118 ↗